Under the deal, Cenexi will make and process the peptides, produce the sterile emulsion, and package clinical batches of the vaccine that is being used in the ongoing phase I clinical trial. The next-generation candidate is a multitarget, multivariant vaccine. The manufacturing will occur at Cenexi's site in Hérouville-Saint-Clair in Normandy, France. The site has a filling capacity of 40 million bottles annually.

Financial details of the agreement were not disclosed.

OSE Immunotherapeutics wide-acting COVID-19 vaccine to enter trials
OSE Immunotherapeutics will shortly begin a phase I clinical trial evaluating CoVepiT, its COVID-19 vaccine candidate on 48 healthy volunteers in Belgium.

Clinical pipeline promises effective 2nd-generation COVID-19 vaccines
Despite the small number of COVID-19 vaccines that have been granted emergency use authorizations by the U.S. Food and Drug Administration to date, many...

EPO grants OSE patent for its anti-IL-7R antagonist
OSE Immunotherapeutics has been granted a patent by the European Patent Office (EPO) for the intellectual property rights for its anti-interleukin-7 receptor...

OSE, MabSilico collaborate on AI-driven mAb development
OSE Immunotherapeutics and MabSilico have partnered to use artificial intelligence (AI)-based software for therapeutic monoclonal antibody (mAb) drug...